Rheumatic disease often affects young adults in the reproductive age group. Management of these diseases with immunosuppressive disease-modifying antirheumatic drugs (DMARDs) is often linked with potential risks for the developing fetus and adverse pregnancy outcomes. This article outlines the study that reviews recent literature on safety during pregnancy for conventional DMARDs .
Several rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) often occur in young females in the childbearing age. Treatment of rheumatic diseases in such patients with potent immunosuppressive agents requires a balance between the consequences of potential disease-related damage and the risk of infertility or adverse pregnancy outcomes. The majority of the inferences regarding safety are drawn from animal experiments and analyses of retrospective data because it is…
